Cardiac allograft vasculopathy (CAV) is a major limitation to long-term survival after heart transplantation. Innovative new techniques to diagnose CAV have been applied to detect disease. This review will examine the current diagnostic and treatment options available to clinicians for CAV.
INTRODUCTION
Heart transplantation remains the gold standard for treatment of stage D heart failure, resulting in improved quality of life, exercise capacity, and survival. Whereas post-transplant survival has improved from a median of 8 years in the 1980s to over 12 years in 2016, this gain is primarily attributable to improved first year survival [1] . Following the first year, cardiac allograft vasculopathy (CAV) is the third most common cause of death after heart transplantation. Graft failure is listed as distinct cause of death, but most cases of graft failure are from CAV. If graft failure is included, then CAV is the most common cause of long-term mortality [1] . CAV is observed in 30-45% of heart transplantation recipients by 5 years post-transplant and 50-65% by 10 years [1, 2] .
Cardiac allograft vasculopathy is a distinct form of vascular disease unique to the coronary arteries of heart transplantation recipients. It is characterized by diffuse epicardial neointimal hyperplasia [3] , concentric medial microvascular disease [4] , and impaired coronary blood flow [5] . Findings of coronary artery luminal narrowing are attributable to restrictive remodeling from external elastic lamina constriction [6] . (Fig. 1) The causes of CAV are multifactorial: 'nonimmunologic damage' [organ preservation, ischemia reperfusion injury, donor brain death, infection (cytomegalovirus), and donor hypertension, age, and sex match], 'immune-mediated injury' (donor-specific antibodies, antibodymediated and cellular rejection, inflammatory cytokines), and 'atherosclerotic' (diabetes, hypertension, dyslipidemia).
INVASIVE TESTING

Coronary angiography
The original Gao angiographic criteria for CAV [7] to describe anatomic lesions (type A, B1, B2, and C lesions) was replaced in 2010 with the current
Intravascular ultrasound
Intravascular ultrasound (IVUS) utilizes ultrasound to visualize the coronary lumen and layers of the arterial wall (Fig. 3) . IVUS performed 4-6 weeks after transplantation identifies donor disease if maximal intimal thickness (MIT) exceeds 0.5 mm. When compared to IVUS, the sensitivity of angiography to detect CAV ranges from 43 to 44% [10, 11] . IVUS also provides important prognostic information, because an MIT of at least 0.5 mm or an increase from baseline to 1-year post-heart transplantation of at least 0.5 mm has been linked to future angiographic CAV, death, graft loss, and myocardial infarction [12] [13] [14] [15] . IVUS also allows virtual histology, which uses backscatter radiofrequency data to generate a tissue map that characterizes vessel wall composition (fibrous, fibro-fatty, necrotic core, and dense calcium) with 87-96% in-vivo accuracy [16] . Using this technique, plaques identified as inflammatory (necrotic core and dense calcium >30%) have been shown to predict CAV progression [17] . Limitations of widespread IVUS use have been cost, operator experience, and potential risk. IVUS is well tolerated, with reversible arterial spasm being the most common complication (up to 2.9%, but less with nitroglycerin pretreatment) and rare acute complications (0.4% risk of occlusion, embolism, dissection, or thrombus) [18, 19] .
Optical coherence tomography
Optical coherence tomography (OCT) is a lightbased technology that allows intracoronary imaging with 10 times the spatial resolution of IVUS (10-20 mm), providing clear delineation of the arterial intima and media (Fig. 4) . This increased resolution permits in-vivo vessel histological analysis [20] OCT has superior interobserver correlation [21] and has been successfully used to screen for CAV [22] [23] [24] . Whereas OCT-derived MIT presumably has the same prognostic significance as IVUS-measured MIT, outcomes data are lacking at this time. A commonly cited drawback for OCT has been the need for additional contrast media (8-10 ml); however, both dextran and saline may be used rather than contrast [25] .
Coronary flow
Impaired myocardial blood flow is a consequence of both epicardial and microvascular CAV [5, 26] . By placing a pressure wire in the coronary artery, blood flow throughout the coronary vasculature can be quantified. Specific measurements include the following: fractional flow reserve (FFR) for the epicardial arteries, index of microcirculatory resistance (IMR) for the microvasculature, and total coronary flow with the coronary flow reserve (CFR) (Fig. 5 ).
Among nontransplant patients, a decreased FFR [27, 28] , decreased CFR [29, 30] , and increased IMR [31] have all been associated with an increased risk of adverse cardiovascular events. Intracoronary flow measures are not as well studied for CAV, but are promising granted the pathophysiology of CAV. In one study, a CFR less than 2.0 had a sensitivity of 79% and negative predictive value (NPV) of 93% to predict angiographic CAV (>50% stenosis) or cardiac death [32] . However, this finding has not been replicated [33 & ]. Abnormal microvascular function 1 year after heart transplantation, defined as an IMR at least 20, portends a 250% increased risk of death, graft failure, or CAV at 5 years after transplant [34] . Further, at 1 year after heart transplantation, a FFR less than 0.90 leads to a 37% absolute increase in mortality, and an IMR at least 20 leads to a 30% absolute increase in death or retransplantation at 5 years. Although additional studies are needed to confirm these findings and to define implications of abnormal coronary flow parameters later after heart transplantation, this is a diagnostic technique with great potential.
NONINVASIVE TESTING
Stress echocardiography
Exercise stress echocardiography is hindered by the impaired heart rate response of heart transplant recipients, resulting in a sensitivity of only 15-33% [35, 36] , to diagnose angiographic CAV. Dobutamine stress echocardiography (DSE) is the most commonly employed noninvasive test screening for CAV (Fig. 6 ). Early studies (the largest included 109 patients) compared DSE to coronary angiography and demonstrated sensitivities and NPVs ranging from 65 to 95% and 71 to 92%, respectively [37] [38] [39] [40] [41] [42] . Subsequent studies comparing DSE to IVUS diagnosed CAV again showed adequate sensitivity (72-79%) and NPV (62-71%) [39, 41] . A positive DSE has also previously been associated with increased risk of cardiac events and death [43] . Recently, two independent studies including over 500 patients questioned the adequacy of DSE to detect angiographic CAV, finding that in clinical practice, the sensitivity of DSE was only 6.5% in ISHLT CAV1, 27% in ISHLT CAV2, and 24% in ISHLT CAV3 [44 & ,45 & ].
Contrast-enhanced transthoracic echocardiography
Contrast-enhanced transthoracic echocardiography (CETE) with CFR has been employed to screen for CAV. In a study of 22 patients 6 years after heart transplantation, CFR was inversely related to MIT, and a CFR cut-off of 2.9 had good sensitivity (80%) and specificity (100%) to diagnose IVUS-confirmed CAV [46] . Similarly, CETE with CFR may diagnose angiographic CAV (82% sensitive, 87% specific) [47] , and decreased CFR by this technique has been associated with an increased risk of MACE [48] . This modality requires excellent echocardiographic images and may be limited in heart transplantation patients with poor acoustic windows, and has limited reproducibility.
Coronary computed tomography angiography
Coronary computed tomography angiography (CCTA) was called 'promising' in the most recent ISHLT guidelines (class IIb recommendation) to diagnose CAV [8] . A 2013 meta-analysis [49] found CCTA to be on par with coronary angiography to diagnose any CAV, with a sensitivity of 97% and NPV of 88%. However, an analysis comparing CCTA to IVUS demonstrated the limitations of both CCTA and angiography, as the sensitivity and NPV of CCTA were 81 and 50%, respectively. Limitations of this technique include a limited ability to detect small vessel disease, need for heart rates below 65 (unless a dual source scanner is used), radiation exposure ($8-12 msV), and contrast exposure (60-120 ml).
Myocardial perfusion imaging
Single-photon emission computed tomography Similar to stress echocardiography, exercise singlephoton emission computed tomography (SPECT) myocardial perfusion imaging (MPI) is limited to diagnose CAV. Pharmacologic stressors improve the ability of SPECT to diagnose CAV, as dobutamine SPECT has a sensitivity and NPV of 89-90% and 79-96%, respectively [50, 51] . Reports vary regarding the ability of dipyridamole SPECT to detect stenosis at least 50%, with sensitivity and specificity ranging from 21 to 92% and 86 to 92%, respectively [52] [53] [54] , and may miss luminal disease (sensitivity 56%) [52] . Negative studies are prognostic as the NPV for dobutamine SPECT is 95-98% for adverse cardiac events over the next 12 months [50, 55] , and is 78% over 6 years for dipyridamole SPECT [52] . The main limitation of this technique is radiation, which can range from 4 to 24 mSv [56] . Additionally, given the diffuse nature of CAV, balanced ischemia may be missed.
Positron emission tomography
Cardiac positron emission tomography (PET) stress testing provides superior perfusion information compared to SPECT, and PET also quantifies myocardial blood flow. Measurement of CFR by PET allows detection of microvascular disease and/or diffuse balanced ischemia (Fig. 7) . Among nontransplant patients, a decreased CFR measured by PET is associated with increased mortality with up to 10 years of follow-up [29, 30, 57] . Two single-center studies of PET to screen for CAV found an association with future adverse cardiac events [58, 59] . Moreover, whereas this technique also exposes the patient radiation, it is significantly less ($2 mSv) [56, 60] .
Cardiac magnetic resonance imaging Cardiac magnetic resonance (CMR) imaging is not widely used to diagnose CAV. A small study demonstrated CMR imaging coronary angiography had a modest ability to detect any angiographic CAV in vessels greater than 1.5 mm (sensitivity 60% and specificity 100%) [61] . Similar to PET, CMR imaging can quantify coronary blood flow and adenosine stress CMR imaging derived myocardial blood flow has been shown to be able to identify both epicardial and microvascular CAV in three small studies [62] [63] [64] . Limitations of CMR include the need for lower heart rates, the risk of nephrogenic systemic fibrosis due to gadolinium administration in patients with impaired renal function, and implanted or retained non-MRI compatible devices.
Biomarkers
At present, no biomarker capable of diagnosing CAV has been identified. Several biomarkers have been associated with an increased risk of developing CAV, including donor specific anti-HLA antibodies [65] [66] [67] [68] , persistent troponin elevation after the first month [69] , elevated von Willebrand factor [70] , and a combination of an elevated N-terminal probrain natriuretic peptide (NT-proBNP) and C-reactive protein (CRP) [71] .
PREVENTION
Statins
Since the initial trial demonstrating the benefits of pravastatin [72] , statin therapy has become standard of care following heart transplantation (class I, LOE A) [8] . The study found that pravastatin initiated 2 weeks after heart transplantation not only lowered cholesterol, but also reduced hemodynamically significant rejection, improved 1-year survival, and decreased the incidence of CAV (and persisted to 10 years) [8] . Subsequent studies have found similar benefits with other statins [73] [74] [75] [76] , and a metaanalysis of nine studies found statins decreased the odds of death by 76%, CAV by 67%, hemodynamically significant/fatal rejection by 63%, and terminal cancer by 70% [77] Aspirin Heart transplantation recipients have been shown to have increased ADP-induced platelet aggregation [78] , and increased platelet aggregation has been associated with CAV [79] . However, the use of aspirin in heart transplantation recipients is empirical as there is no evidence demonstrating improved outcomes with its use.
Diltiazem
A study before the use of statins found diltiazem was associated with preservation of coronary artery diameter and improved post-transplant survival [80] . However, this finding was not confirmed with concomitant statin use [81] .
Mycophenolate mofetil
Following transplantation use of mycophenolate mofetil (MMF) or a proliferation signal inhibitor (PSI) carries a class IIa, LOE B recommendation to reduce the onset and progression of CAV [8] . In 660 de-novo heart transplantation recipients, when compared to azathioprine, MMF at 1500 mg twice a day resulted in a 7% absolute decrease in death or retransplantation and also decreased MIT progression as measured by IVUS [82] .
Proliferation signal inhibitors
The class IIa recommendation [8] for PSIs is principally based on studies that introduced PSIs at the time of transplantation or soon after [82] [83] [84] [85] . The first study supporting PSI use studied 634 de-novo heart transplant recipients comparing two doses of everolimus (1.5 and 3.0 mg/day) to azathioprine. This study found a 17% absolute risk reduction at 1 year for a combined clinical endpoint that included CAV; however, there was no difference in mortality [83] . Subsequently, this trial was repeated using MMF as a comparator, and again everolimus was found to be superior to MMF (14% absolute risk reduction) for the prevention of CAV, but only noninferior for mortality at 1 year [84, 85] .
TREATMENT
Proliferation signal inhibitors
The current ISHLT guidelines recommend the introduction of a PSI in place of MMF for patients with established CAV (class IIa, LOE B) [8] . In a trial of 46 patients with established CAV rapamycin was found to decrease a combined endpoint of death, worsening CAV, or need for coronary intervention [86] . However, the widespread adoption of rapamycin has been limited by tolerability. A substudy of the Nordic Certican Trial in Heart and Lung Transplantation trial included 111 patients that completed IVUS examination at a median of 5.8 years after transplantation, who were treated with everolimus [and lowdose calcineurin inhibitor (CNI)] or regular immunosuppression. Over half (52%) had CAV (defined at MIT >0.5 mm), and disappointingly there was no difference in progression of CAV between each arm after 1 year of follow-up. A more troubling finding was the suggestion that there was greater progression of CAV when everolimus was used with MMF (without a CNI) [87] . And again, there was no evidence of a mortality benefit with PSI use.
Revascularization
Percutaneous coronary intervention As a result of the diffuse nature of CAV, percutaneous coronary intervention (PCI) has limited effectiveness to treat CAV. Trials have demonstrated that early restenosis is frequent with both balloon angioplasty (41-67%) and stenting (25-64%) [88, 89] , and that any early success with bare metal stenting is mitigated by 5 years when restenosis rates reach 69% [88] . The use of drug eluting stent may reduce the risk of restenosis [90] , but have not been shown to improve survival [91] . In a single-center study, patients with ISHLT CAV 3 that was amenable to PCI and who underwent PCI had a decreased odds of death at 2 [odds ratio (OR) 0.26, 95% confidence interval (CI) 0.08-0.82] and 5 years (OR 0.28, 95%
CI 0.09-0.93) compared to patients with ISHLT CAV 3 not amenable to PCI [92] . Thus, it is reasonable to perform PCI for CAV that is amenable to PCI as a palliative treatment.
Coronary artery bypass grafting
Coronary artery bypass grafting (CABG) should be used with caution as it carries both a high perioperative (up to 40%) and 1-year mortality (up to 58%) [93] [94] [95] .
Implantable cardioverter defibrillator
Sudden cardiac death is one of the modes of mortality for patients with CAV. Implantable cardioverter defibrillator (ICD) has been shown to decrease the risk of sudden cardiac death among patients with a depressed ejection fraction, and ischemic heart disease, however, is not well studied among heart transplantation recipients. The most common indications for ICD use in heart transplantation recipients are low ejection fraction, ISHLT CAV 3, unexplained syncope, survived cardiac arrest, and ventricular arrhythmias [96, 97] . In one study, 10 of 36 patients received shocks and 80% received appropriate shocks [97] . However, there has been no evidence to support that ICDs improve survival in those with CAV and ICD implantation in the setting of immunosuppression is not without risk.
Retransplantation
Retransplantation is considered the only definitive therapy for CAV. Early results with retransplantation were poor with low 1-year (54%) and median survival (less than 2 years). Subsequently, it was found that the timing of retransplantation matters; when performed within the first year following primary transplantation postretransplant 1-year survival is 53%, whereas retransplantation after 1 year has significantly improved 1-year survival (78-81%). Similarly, 1-year survival for retransplantation secondary to CAV (typically after 1 year) is 81% compared with less than 60% 1-year survival when used for primary graft failure [98] . Furthermore, whereas still inferior to primary transplant, median survival is now 10 years [98] . Biventricular mechanical circulatory support as a bridge to retransplantation has been reported to have good pre and postretransplant outcomes [99] ; however, the use of extracorporeal membrane oxygenation should be avoided [100] .
CONCLUSION
Cardiac allograft vasculopathy is prevalent following transplantation and has a high associated mortality. The currently recommended diagnostic techniques (coronary angiography, DSE) lack the sensitivity of techniques that measure coronary arterial wall thickening and coronary blood flow. Treatment of CAV remains a challenge for clinicians as therapeutic options are limited. Future research is needed to determine novel treatments for CAV and the optimal time to institute currently available treatment.
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